Document is current

Article History

Received: 15 May 2019

Accepted: 8 November 2019

First Online: 28 November 2019

Ethics approval and consent to participate

: The ethics committees of all contributing institutions approved the protocol for this study.

: Not applicable

: WF received speaking fees from Eizai, Ono Pharmaceutical Co. Ltd. (Ono), Takeda Pharmaceutical Co. Ltd. (Takeda), Daiichi-Sankyo Co. Ltd. (Daiichi-Sankyo), Astellas Pharm Inc. (Astellas), Mitsubishi-Tanabe Pharm (Mitsubishi-Tanabe), Pfizer Japan Inc. (Phizer), Asahi-Kasei Pharma (Asahi-Kasei), Janssen Pharmaceutical KK (Janssen), and Eli Lilly Japan K.K. (Eli Lilly) (less than $10,000 each). TH received speaking fees from AbbVie GK (AbbVie), Eli Lilly, Daiichi-Sankyo, Mitsubishi-Tanabe, Chugai Pharmaceutical Co. Ltd. (Chugai), and Ayumi Pharmaceutical Co. (Ayumi) (less than $10,000 each). SM received speaking fees from Ono, Daiichi-Sankyo, Astellas, Mitsubishi-Tanabe, Pfizer, Janssen, AbbVie, Chugai, and Eli Lilly (less than$10,000 each). MM received speaking fees from Chugai, AbbVie, Bristol-Myers Squibb Company (BMS), Eisai, Takeda, Janssen, Eli Lilly, Pfizer, and UCB Japan Co. Ltd. (UCB) (less than $10,000 each). YK received speaking fees from Ayumi, BMS, Chugai, Asahi-Kasei, and Eli Lilly (less than $10,000 each). TK received speaking fees from AbbVie, Asahi-Kasei, BMS, Chugai, and Mitsubishi-Tanabe (less than $10,000 each). HH received speaking fees from BMS, Chugai, Eizai, Daiichi-Sankyo, Astellas, Mitsubishi-Tanabe, Pfizer, Asahi-Kasei, Teijin Pharma Ltd., and GlaxoSmithKline KK (less than $10,000 each). YI received speaking fees from Asahi-Kasei (less than $1,000). TS received speaking fees from AbbVie, BMS, Chugai, UCB, Astellas, Mitsubishi-Tanabe, and Asahi-Kasei (less than $10,000 each). Atsushi Omoto received speaking fees from AbbVie, Chugai, Eizai, Ono, Takeda, Daiichi-Sankyo, Astellas, Mitsubishi-Tanabe, Pfizer, Asahi-Kasei, and Eli Lilly (less than $10,000 each). TS belonged to the affiliation stipulated, but by the time this manuscript had been developed, TS became an employee of Astellas. S.M. received honoraria from AstraZeneca K.K., BMS, Chugai, Eli Lilly, MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Ono, Pfizer, Kyowa Hakko Kirin, and Taiho Pharmaceutical Co. Ltd. MK, Akitimo Okada, YH, MH, KA, YU, TY, and SI declare that they have no competing interests.